Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 -0.8%	$1.27	$0.86 ▼ $3.78	$260.29M	0.31	3.26 million shs	1.38 million shs
CING Cingulate	$4.30 -1.0%	$4.11	$1.80 ▼ $20.83	$18.24M	-0.79	1.10 million shs	40,442 shs
ENGN enGene	$3.88 +3.7%	$3.62	$2.65 ▼ $11.00	$198.27M	-0.42	128,170 shs	45,357 shs
LENZ LENZ Therapeutics	$32.54 +5.1%	$28.93	$16.54 ▼ $38.93	$915.73M	0.42	191,046 shs	103,393 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	-0.83%	-0.83%	-11.85%	-17.36%	-42.79%
CING Cingulate	-1.04%	+4.76%	+7.91%	+13.62%	+1,242.19%
ENGN enGene	+3.74%	+8.08%	-7.62%	-13.78%	-56.84%
LENZ LENZ Therapeutics	+5.09%	+8.05%	+9.29%	+53.61%	+84.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.0559 of 5 stars	4.5	1.0	0.6	3.3	0.6
CING Cingulate	3.0181 of 5 stars	3.5	4.0	2.8	0.8	0.6
ENGN enGene	2.6747 of 5 stars	3.5	3.0	1.0	2.5	0.6
LENZ LENZ Therapeutics	1.4942 of 5 stars	3.6	0.0	2.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	609.62% Upside
CING Cingulate	3.00	Buy	$26.00	505.36% Upside
ENGN enGene	3.00	Buy	$23.29	500.15% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	43.23% Upside

Current Analyst Ratings Breakdown

Latest ENGN, ALLO, CING, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00
5/19/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,014.44	N/A	N/A	$2.01 per share	0.59
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
ENGN enGene	N/A	N/A	N/A	N/A	$4.45 per share	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
CING Cingulate	-$15.55M	-$8.48	N/A	N/A	N/A	N/A	-229.78%	-142.28%	8/12/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	N/A
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)

Latest ENGN, ALLO, CING, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/8/2025	Q1 2025	CING Cingulate	-$1.00	-$1.04	-$0.04	-$1.04	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
CING Cingulate	0.16	1.87	1.87
ENGN enGene	0.09	12.66	12.66
LENZ LENZ Therapeutics	N/A	23.09	23.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CING Cingulate	41.31%
ENGN enGene	64.16%
LENZ LENZ Therapeutics	54.32%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CING Cingulate	5.27%
ENGN enGene	10.40%
LENZ LENZ Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
CING Cingulate	20	4.25 million	4.02 million	Not Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A

ENGN, ALLO, CING, and LENZ Headlines

Recent News About These Companies

LENZ Therapeutics: Presbyopia Eyedrops Look Promising

July 1 at 5:13 PM | seekingalpha.com

LENZ Therapeutics Inc Dividends - Morningstar

July 1 at 11:34 AM | morningstar.comM

Lisanti Capital Growth LLC Purchases New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

June 30, 2025 | marketbeat.com

Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $46.60

June 29, 2025 | americanbankingnews.com

LENZ - LENZ Therapeutics Inc Trailing Returns - Morningstar

June 28, 2025 | morningstar.comM

LENZ Therapeutics Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by Brokerages

June 26, 2025 | marketbeat.com

Versant sells LENZ therapeutics (LENZ) stock worth $10.1 million

June 22, 2025 | investing.com

LENZ Therapeutics: Ready To Test Its Potential

June 16, 2025 | seekingalpha.com

Healthcare companies chase cures and capital in South Florida

June 11, 2025 | sun-sentinel.comS

LENZ Therapeutics (NASDAQ:LENZ) Shares Up 6.3% - Here's Why

June 11, 2025 | marketbeat.com

Two Sigma Investments LP Has $493,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

June 10, 2025 | marketbeat.com

LENZ Therapeutics (NASDAQ:LENZ) Shares Down 5.9% - Here's What Happened

June 9, 2025 | marketbeat.com

Bank of America Corp DE Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

June 7, 2025 | marketbeat.com

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision

May 29, 2025 | uk.investing.com

LENZ Therapeutics to Present at Upcoming Investor Conferences

May 27, 2025 | manilatimes.netM

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment

May 12, 2025 | msn.com

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive

May 9, 2025 | uk.investing.com

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 9, 2025 | globenewswire.com

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
Hims & Hers Stock: Buy the Dip or Wait It Out?
By Gabriel Osorio-Mazilli | June 5, 2025
View Hims & Hers Stock: Buy the Dip or Wait It Out?
Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
By Jeffrey Neal Johnson | June 8, 2025
View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
UPS Is Outpacing the Market: A Green Light for Investors?
By Jeffrey Neal Johnson | June 27, 2025
View UPS Is Outpacing the Market: A Green Light for Investors?

ENGN, ALLO, CING, and LENZ Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.19 -0.01 (-0.83%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$1.19 0.00 (0.00%)

As of 07/3/2025 04:56 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Cingulate NASDAQ:CING

$4.30 -0.05 (-1.04%)

Closing price 07/3/2025 03:37 PM Eastern

Extended Trading

$4.30 0.00 (0.00%)

As of 07/3/2025 04:55 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

enGene NASDAQ:ENGN

$3.88 +0.14 (+3.74%)

As of 07/3/2025 03:56 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

LENZ Therapeutics NASDAQ:LENZ

$32.53 +1.58 (+5.09%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$32.53 0.00 (0.00%)

As of 07/3/2025 04:19 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time